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Abstract
Background: Cloning of cattle by somatic cell nuclear transfer (SCNT) is associated with a high incidence of
pregnancy failure characterized by abnormal placental and foetal development. These abnormalities are thought to
be due, in part, to incomplete re-setting of the epigenetic state of DNA in the donor somatic cell nucleus to a
state that is capable of driving embryonic and foetal development to completion. Here, we tested the hypothesis
that DNA methylation patterns were not appropriately established during nuclear reprogramming following SCNT.
A panel of imprinted, non-imprinted genes and satellite repeat sequences was examined in tissues collected from
viable and failing mid-gestation SCNT foetuses and compared with similar tissues from gestation-matched normal
foetuses generated by artificial insemination (AI).
Results: Most of the genomic regions examined in tissues from viable and failing SCNT foetuses had DNA
methylation patterns similar to those in comparable tissues from AI controls. However, statistically significant
differences were found between SCNT and AI at specific CpG sites in some regions of the genome, particularly
those associated with SNRPN and KCNQ1OT1, which tended to be hypomethylated in SCNT tissues. There was a
high degree of variation between individuals in methylation levels at almost every CpG site in these two regions,
even in AI controls. In other genomic regions, methylation levels at specific CpG sites were tightly controlled with
little variation between individuals. Only one site (HAND1) showed a tissue-specific pattern of DNA methylation.
Overall, DNA methylation patterns in tissues of failing foetuses were similar to apparently viable SCNT foetuses,
although there were individuals showing extreme deviant patterns.
Conclusion: These results show that SCNT foetuses that had developed to mid-gestation had largely undergone
nuclear reprogramming and that the epigenetic signature at this stage was not a good predictor of whether the
foetus would develop to term or not.
Background
Somatic cell nuclear transfer (SCNT) has been used to
successfully produce cloned animals from several mam-
malian species since a sheep was cloned using a differen-
tiated somatic donor cell [1]. However, to date
widespread application of SCNT in agricultural breeding
programs has not yet been captured because the technol-
ogy remains inefficient despite more than 10 years of
research. Irrespective of the species being cloned, there is
still a high rate of pregnancy failure throughout gestation
[2-6]. The most common SCNT foetal phenotypes across
species are foetal overgrowth and loss of allometric
growth regulation (collectively known as “large offspring
syndrome”), musculoskeletal defects, and acute, excessive
accumulation of allantoic fluid (hydrallantois or hydrops)
accompanied by perturbations in the composition of this
fluid [7]. In cattle, the large offspring syndrome appears
to be independent of the donor cell genetics.
Many of the developmental defects observed in cloned
bovine foetuses suggest the involvement of growth
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imprinted. Some of these genes play key roles in regulating
cellular proliferation, growth and development of the foe-
tus and the placenta (reviewed [8]). The phenotypes com-
monly observed in SCNT foetuses bear many similarities
to some of those seen in experimentally-created imprint-
ing disruptions in mice (silencing of both alleles or biallelic
expression of imprinted genes), or to naturally-occurring
human syndromes, such as Beckwith-Wiedemann syn-
drome (BWS) [9-13]. These similarities suggest that the
expression of some of these imprinted genes is abnormal
and/or that these genes are not appropriately repro-
grammed following SCNT. Furthermore, SCNT calves
dying shortly after birth were shown to have abnormal
expression of imprinted genes in a variety of organs when
compared to controls generated by AI [14]; this was not
the case in surviving adult clones [15,16]. During the
development of multicellular organisms, different cells and
tissues acquire different programs of gene expression. It is
thought that a substantial part of this gene regulation is
mediated through epigenetic modifications such as DNA
methylation, histone tail modifications and the binding of
non-histone proteins to chromatin [17-19] so that each
somatic cell in the organism has its own epigenetic signa-
ture (epigenome) which reflects its genotype, developmen-
tal history and environmental influences, which ultimately
determines the phenotype of the cell and the organism.
This is clearly illustrated in the events following fertiliza-
tion, where the majority of the genome undergoes active
paternal demethylation, then passive maternal demethyla-
tion. Re-methylation of the genome then occurs during
repeated mitosis as cells progress towards lineage commit-
ment and the development of the embryo proper and the
placenta [18,20-22]. How the developmental programs are
coordinated and orchestrated from the genomic blueprint
is still poorly understood, even in normal development.
In reproductive cloning by SCNT, the epigenetic sig-
nature of a differentiated somatic cell must be reset to a
state resembling totipotency, capable of driving full
development after fusion of the cell with an enucleated
oocyte cytoplast. Incomplete nuclear reprogramming is
widely postulated to be a major contributor to the low
developmental success rate following SCNT. Evidence to
support this include observed hypo-methylation [23-26],
hyper-methylation [27,28], or mosaic methylation states
[29] in tissue samples collected from abnormal foetuses
or cloned calves that died shortly after birth. Normal
methylation following SCNT has also been reported
[28,30,31], suggesting a degree of stochasticity in nuclear
reprogramming. The variable findings from different
studies are due to different genes or genomic regions
examined, different tissues used and controls that were
not gestation- or age-matched. This has made compari-
sons between previous studies difficult.
Cloned animals that reach maturity are able to repro-
duce normally and give rise to normal offspring without
the high rate of pregnancy failure or large offspring syn-
drome associated with SCNT [32,33], suggesting that
underlying cause/s of the abnormalities associated with
SCNT is/are epigenetic.
In this study, we examined the DNA methylation pat-
terns in a panel of candidate genes using tissues from
three foetal organs (liver, kidney and adrenal glands) of
similar gestations generated by either SCNT or AI.
These organs were selected because of the pivotal roles
they play in foetal metabolism, nutrient sensing and
hematopoiesis (liver), regulation of blood pressure and
foetal fluid homeostasis (kidney) and foetal endocrinol-
ogy (adrenal glands). As most cases of hydrallantois
occur from or just after mid-gestation, the selection of
this stage of gestation allowed us to compare samples
from foetuses that showed clear physiological and anato-
mical abnormalities with those that had not yet exhib-
ited these symptoms and thus, had the potential to
develop to further.
The genes selected consisted of those known to be
imprinted in other species, non-imprinted genes and
repeat sequences (satellites 1, 2 and alpha). The
imprinted genes include those associated with BWS,
s u c ha sI G F 2 ,K C N Q 1 ,C D K N 1 C ,K C N Q 1 O T 1 ;o t h e r s
such as ASCL2, HAND1, DIO3; and SNRPN, a gene in
the Prader-Willi and Angelman syndrome locus. The
non-imprinted genes include colony stimulating factor
( C S F - 1 ) ,S T A T 5 a ,D K K - 1 ,a n dG R ,w h i c hc o d e sf o rt h e
glucocorticoid receptor, that mediates the action of glu-
cocorticoids and mineralcorticoids, both important in
regulation of fluid composition. The CpG islands exam-
ined included those located upstream of transcriptional
start sites or within the gene itself or in equivalent
regions shown in other species to be differentially
methylated regions (DMRs) and normally associated
with imprinted genes. The SNRPN site is equivalent to
the imprinting centre (IC) of the human gene [34]
which has been shown to be aberrantly methylated in
the Prader-Willi (PWS) and Angelman syndromes [35].
The KCNQ1OT1 region is equivalent to the human
KCNQ1OT1 DMR which was found to be hypomethy-
lated at increased frequency in human IVF offspring
[12,36,37]. Together, this selection of genomic
sequences allowed us to assess how well these different
regions were re-programmed after nuclear transfer in
embryos that were capable of developing at least to
mid-gestation.
Results
Pregnancy rates in SCNT and AI
From the first ultrasound scan at Day 35, 29 of the 42
(69%) SCNT recipient dams that received a Day 7
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10 days prior to the development of the first SCNT
hydrops case, only 14 were still pregnant (33%). Four
subsequently developed clinical hydrops and were
slaughtered. For the AI group, 13 of the 18 (72%) recipi-
ents inseminated were pregnant at Day 35, 11 of these
still pregnant (61%) at Day 130; none showed signs of
abnormal fluid accumulation.
DNA methylation analysis
DNA methylation analysis at each of the listed genomic
regions was performed from the same genomic DNA for
each sample. Because the cleavage of the transcribed
RNA is sequence-specific, some fragments may contain
only one CpG site whilst others may contain up to 6
CpG sites where the CpG dinucleotides were arranged
consecutively in the sequence or close together. Where
multiple CpG sites occurred within a fragment, the
methylation level reported by the EpiTYPER software
was that of the most highly methylated site. Where is
was not possible to resolve two fragments with the same
mass but with different sequences, the methylation level
is recorded as an average of the two fragments. The
number of CpG sites or group of sites that could be
analyzed for each region is given in each figure legend.
Imprinted genes
IGF2 exon 10
The CpG island located in IGF2 exon 10 was highly
methylated (70-100%) at almost all CpG sites in
all three tissues examined and in all treatment groups
(figure 1). There was a high level of variation in methy-
lation levels between individual samples, even in nor-
mal control tissues. Only the adrenal tissues showed a
significant difference in mean methylation between AI,
SCNT and SCNT-hydrops groups; SCNT-hydrops sam-
ples tended to be hypermethylated compared with the
AI or SCNT samples. At CpG 5, individual SCNT and
SCNT-hydrops adrenal samples were either completely
methylated or unmethylated, whereas the AI samples
were methylated to between 30-40%. No notable tis-
sue-specific methylation patterns were observed. When
averaged over the entire region analyzed, the methyla-
tion levels ranged from 65 to 85% for all three tissues
(figure 1d). A significant difference was detected in the
regional mean methylation levels between the AI and
SCNT (P = 0.01) and SCNT-hydrops (P = 0.03) in the
adrenal samples, and in the kidney between AI and
SCNT (P = 0.04) and between SCNT and SCNT-
hydrops (P < 0.001). Three of the SCNT-hydrops sam-
ples were almost 100% methylated at every site whilst
another was methylated at between 40-50% at almost
every site, illustrating the level variation between some
i n d i v i d u a l si nt h i sg r o u p .
ASCL2
Compared with the IGF2 exon 10 region, the DNA
methylation levels here were low (less than 25%) in all
tissue samples (figure 2). Furthermore, the variation
between individuals was very small in all three tissues,
resulting in a mean percentage methylation at each CpG
site that was remarkably similar between the treatment
Figure 1 DNA methylation at the IGF2 exon 10 DMR. Sixteen
cleavage fragments containing 24 out of a total of 34 CpG sites in
this region could be analyzed. The pairs of cleavage fragments
containing CpG sites 6 and 23; 7 and 8-9; 17 and 24; 18-19 and
25-27; could not be distinguished from each other in the analysis.
Therefore, the proportion of methylation in each of these fragment
pairs is represented as an average value.
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consistently methylated at higher levels (20-25%) com-
pared with other fragments/sites (0-10%) examined in
every sample. This difference is likely due to the algo-
rithm used by EpiTYPER to determine methylation levels
in fragments containing multiple CpG sites [38]. Despite
the apparent similarity in mean methylation levels in the
fragments analyzed, significant differences between AI,
SCNT and SCNT-hydrops groups were found in certain
fragments in all three tissues (figure 2). The mean DNA
methylation level across this region was similar in all
groups across all tissues (figure 2d).
HAND1
DNA methylation levels at this CpG island in the pro-
moter region of HAND1 were mostly low (0-20%) in
kidney and liver tissues (figure 3). Interestingly, the
adrenal tissues from all three groups showed higher
methylation levels (10-55%) and greater variability at
most CpG sites across this region when compared with
either liver or kidney samples. The only statistically sig-
nificant difference in the mean methylation levels
between treatment groups was in the liver (figure 3c);
however the difference in methylation levels was very
Figure 2 DNA methylation at the region surrounding the
ASCL2 transcription start site. Fourteen cleavage fragments
containing 26 out of a total of 47 CpG sites in this region could be
analyzed. The groups of cleavage fragments containing CpG sites 1
and 27 and 45; 2 and 15-16 and 46-47; 13-14 and 43-44 could not
be distinguished from each other in the analysis. Therefore, the
proportion of methylation in each of these fragment groups is
represented as an average value.
Figure 3 DNA methylation in the region immediately upstream
of HAND1 exon1. Twenty one cleavage fragments containing 28
out of a total of 34 CpG sites in this region could be analyzed. The
groups of cleavage fragments containing CpG sites 1 and 8 and 19;
4-5 and 15; 6 and 25-26; 9-10 and 21; 11-12 and 30-21 could not be
distinguished from each other in the analysis. Therefore, the
proportion of methylation in each of these fragment groups is
represented as an average value.
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CpG site/s were not different among the treatment
groups. The mean level of DNA methylation across the
region was similar between the groups in kidney and
liver tissues but a significant difference was observed in
adrenal tissue (figure 3d) where SCNT samples were sig-
nificantly less methylated compared with either AI or
SCNT-hydrops samples (P < 0.002). For the adrenal tis-
sues, within the SCNT-hydrops group, there were two
individuals cloned from the same donor somatic cell
line: one was consistently methylated to between 30-
70% at practically every analyzable CpG site whereas the
other was methylated to only about 10% for all but
three analyzable CpG sites.
KCNQ1
The percentage of DNA methylation in the KCNQ1
region examined varied from 0-45% across individual
CpG sites, with most showing less than 20% methylation
(figure 4). Overall, the methylation levels of the samples
from all three groups were similar at individual CpG sites
in all tissues examined, although significant differences
among the groups were detected in some fragments
(figure 4a and 4c). No tissue-specific methylation patterns
were observed and the homogeneity of the methylation
levels in all the samples was reflected in the lack of differ-
ence in the mean regional methylation levels between the
tissues and groups examined (figure 4d).
CDKN1C
The methylation pattern in this CpG island, which is
within the transcribed region of CDKN1C, was very
similar across all groups and in all tissues (figure 5).
There was little variation at practically every CpG site
between individual samples within each treatment
group; this lack of variation is reflected in the similarity
of the regional mean methylation levels (figure 5d). The
mean methylation levels at individual CpG sites or
groups of CpG sites were between 0-20% with the
exception of one cleavage fragment containing CpG13-
16, which was methylated to 40-45% in every group and
tissue examined. Because this fragment contains four
CpG sites, it was not possible to determine if certain
sites were methylated to a greater extent than others.
CpG6 and CpG22, 23 were always completely unmethy-
lated in every sample. Due to the limited variation
between individual samples in this region, even differ-
ences as small as 2-3% showed statistical significance at
some sites (figure 5b).
SNRPN
The methylation levels at each CpG site/groups of sites
in this region showed a high degree of variation between
individuals in all three tissues and in every treatment
group (figure 6). Although the majority of the sites
showed no significant differences in mean methylation
levels between the treatment groups, DNA from AI
samples tended to be more methylated than SCNT or
SCNT-hydrops, particularly for the adrenal and kidney
samples. In these two organs, the methylation levels in
the AI samples ranged between 30 - 100% for most
CpG sites whereas in the adrenal samples, three each of
the SCNT and SCNT-hydrops samples were almost
unmethylated (<10%); the others were methylated to a
similar extent as the AI samples. Similarly low levels of
methylation in individual SCNT and SCNT-hydrops kid-
ney samples were also observed. Only one SCNT and
Figure 4 DNA methylation in the region spanning the putative
KCNQ1 transcription start site. Twenty cleavage fragments
containing 36 out of a total of 55 CpG sites in this region could be
analyzed. The pairs of cleavage fragments containing CpG sites 2
and 39; 6-7 and 38; 52 and 53-54 could not be distinguished from
each other in the analysis. Therefore, the proportion of methylation
in each of these fragment groups is represented as an average
value.
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methylation in all three tissues whilst others that were
hypomethylated in one tissue showed almost normal
methylation levels in other tissues. The regional mean
methylation levels were significantly higher (P < 0.001)
in the AI adrenal and kidney but not liver samples when
compared with SCNT or SCNT-hydrops (figure 6d).
Only two fragments in kidney tissues showed significant
difference in mean methylation levels (AI>SCNT,
SCNT-hydrops, figure 6b).
A cleavage fragment containing CpG sites 7, 8, and 9
was consistently methylated to ≤10% in every sample
analysed. To eliminate the possibility that this was due to
unknown SNPs resulting in a C to T conversion and thus
loss of CpG sites, a subset of 10 DNA samples were ampli-
fied across this region and the amplicons sequenced. All
samples contained the expected CGCGCG sequence.
KCNQ1OT1
The KCNQ1OT1 region examined corresponds to the
Kcnq1ot1 DMR in the mouse and human genomes.
Figure 5 DNA methylation in the region spanning intron 3 of
CDKN1C. Seventeen cleavage fragments containing 35 out of a
total of 42 CpG sites in this region could be analyzed. The cleavage
fragments containing CpG sites 5 and 20 could not be
distinguished from each other in the analysis. Therefore, the
proportion of methylation in these fragments is represented as an
average value.
Figure 6 DNA methylation in the SNRPN exon 1 region.
Twenty-seven cleavage fragments that contained all 39 CpG sites in
the region were analyzed. The groups of cleavage fragments
containing CpG sites 4, 29 and 31; 10 and 26; 15-16 and 32-34
could not be distinguished from each other in the analysis.
Therefore, the proportion of methylation in each of these fragment
groups is represented as an average value.
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methylation levels between individuals at each CpG site
was large for all three tissues (figure 7). DNA from
SCNT and SCNT-hydrops foetuses tended to be less
methylated in all three organs when compared with AI
samples, resulting in significantly lower regional average
methylation (figure 7d) in the SCNT and SCNT-hydrops
groups (P < 0.001, except the liver, where AI vs. SCNT,
P = 0.03). There was no significant difference between
the SCNT and SCNT-hydrops groups. Where significant
differences were detected between treatment groups at
individual CpG sites (figure 7a and 7b), these differences
were large compared with the differences seen in
CDKN1C and KCNQ1.
DIO3
The DIO3 region examined is a good example of how
widely DNA methylation levels at individual CpG sites/
fragments can vary within a single CpG island (20-
100%). Highly methylated CpG sites appeared to be
interspersed between CpG sites that were methylated at
low levels (figure 8); this variation was seen in all three
tissues and in all treatment groups. Only one CpG site
in liver samples showed significant difference among the
groups (figure 8c). There were no significant differences
among the treatment groups (figure 8d) in regional
average DNA methylation.
Non-imprinted genes
GR
Methylation levels in this region were relatively low (0-
30% in the kidney and adrenal and 0-50% in the liver) at
individual CpG sites (figure 9). Significant difference was
found only in the kidney at once CpG site (figure 9b).
There were no obvious tissue-specific methylation pat-
terns. The mean regional methylation levels were 10-
15% with no difference detected among the treatment
groups in any of the tissues (figure 9d).
CSF-1
Mean methylation levels were relatively low across the
region analyzed (0-30%) with little variation between
individual CpG sites (figure 10) and no tissue-specific
methylation patterns were evident. Although mean
regional methylation levels were not different among the
groups (figure 10d) there were specific CpG sites where
significant differences were detected. These specific CpG
sites were different for each tissue type (figure 10a, b, c).
In all cases, the differences were small.
DKK-1
Mean methylation levels weres i m i l a rt ot h o s er e p o r t e d
for Day 26 trophoblast tissue [39], with all CpG sites
methylated to ~10%, the exception being CpG31, where
mean methylation levels were 40-50%. There were no
significant differences among the three groups.
STAT5a
DNA methylation levels in a CpG island between
STAT5a and STAT5b were mostly below 30% in kidney,
adrenal and liver samples (figure 11). The only differ-
ence between treatment groups was at one CpG site in
Figure 7 DNA methylation at the putative KCNQ1OT1 DMR.
Twenty cleavage fragments that contained all 31 CpG sites in the
region were analyzed. The groups of cleavage fragments containing
CpG sites 12 and 16; 17 and 22 and 29 and 31; 19 and 23, could
not be distinguished from each other in the analysis. Therefore, the
proportion of methylation in each of these fragment groups is
represented as an average value.
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profiles of liver samples in the SCNT-hydrops group
were more variable than those in the AI or SCNT
groups with some CpG sites in certain individuals
almost completely methylated. No differences were
noted between the groups in the mean DNA methyla-
tion levels across the region in any of the tissues
(figure 11d).
Repeat regions
DNA Satellites I, II and alpha
The majority of CpG sites in the Satellite I sequence
examined were methylated to > 80% in all adrenal, kid-
ney and liver samples (figure 12). Four of the CpG sites
(1, 14, 17, and 22) were consistently methylated to
≤ 50% in all tissue types. CpG sites where the mean
methylation levels were significantly different among
the groups were observed in all three tissues types
(figure 12a, b, c).
Figure 8 DNA methylation at the DIO3 polyA signal.T w e n t y
cleavage fragments containing 26 out of a total of 28 CpG sites in
this region could be analyzed.
Figure 9 DNA methylation in the GR promoter.E i g h t e e n
cleavage fragments containing 28 out of a total of 40 CpG sites in
this region could be analyzed. The pairs of cleavage fragments
containing CpG sites 6-7 and 35; 13-14 and 28; 19-20 and 37 could
not be distinguished from each other in the analysis. Therefore, the
proportion of methylation in each of these fragment groups is
represented as an average value.
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sequences were remarkably similar between individuals,
treatment groups and tissue types (figure 13). CpG1 was
invariably 100% methylated, CpG17 was methylated to
30-40%. All other CpG sites were 70-80% methylated.
Only three cleavage fragments in SCNT kidney samples
showed significantly different mean methylation levels
compared with the other two groups (figure 13b).
The Satellite alpha sequences also showed similar
patterns of methylation in all the treatment groups and
tissues (figure 14) with the only significant difference
being found at one CpG site in the kidney (figure 14b).
There were no apparent tissue-specific methylation
patterns. Other than CpG10, which showed a moderate
level of variation between individuals, the other CpG
sites were consistently methylated to the same degree
in every sample, tissue and treatment group. CpG 13
was completely methylated in every sample. No signifi-
cant differences were noted between the three groups
in the mean DNA methylation levels across any of the
Figure 10 DNA methylation at the CSF-1 transcription start
site. Twenty-one cleavage fragments containing 35 out of a total of
58 CpG sites in this region could be analyzed. The pair of cleavage
fragments containing CpG sites 15-18 and 45-47 could not be
distinguished from each other in the analysis. Therefore, the
proportion of methylation in each of these fragment groups is
represented as an average value.
Figure 11 DNA methylation 10 kb upstream of the STAT5a
transcription start site. Nineteen cleavage fragments containing
43 out of a total of 58 CpG sites in this region could be analyzed.
The pairs of cleavage fragments containing CpG sites 14-15 and 32;
16-17 and 24-26; 33 and 58 could not be distinguished from each
other in the analysis. Therefore, the proportion of CpGs methylated
in each of these fragment pairs is represented as average values.
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and 14d).
Discussion
In this study, we addressed the question of whether
nuclear reprogramming has occurred appropriately after
SCNT by examining DNA methylation patterns in tissue
samples collected from three organs from mid-gestation
foetuses. Being able to sub-divide the SCNT group into
those that appeared “viable” at slaughter and those that
were failing as a result of clinical hydrops (SCNT-
hydrops) allowed us to determine if the failing foetuses
were methylated differently compared with those that
had the potential to develop further. As there are no
means to determine, with certainty, the outcome from a
foetus that looked “viable” at mid-gestation (SCNT or
AI), we can only make the assumption that these SCNT
foetuses have the potential, like the AI foetuses, to
develop further. Previous studies have indicated that
Figure 12 DNA methylation across satellite I repeat sequence.
Fifteen cleavage fragments containing 20 out of a total of 23 CpG
sites in this region could be analyzed. The cleavage fragments
containing CpG sites 13 and 20 could not be distinguished from
each other in the analysis. Therefore, the proportion of methylation
in each of these fragment groups is represented as an average
value.
Figure 13 DNA methylation across satellite II repeat sequence.
Ten cleavage fragments containing 18 out of a total of 22 CpG sites
in this region could be analyzed. The cleavage fragments containing
CpG sites 8-9 and 11-12 could not be distinguished from each
other in the analysis. Therefore, the proportion of methylation in
each of these fragment groups is represented as an average value.
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in a live calf [40-43]. In the majority of regions examined,
the DNA from the SCNT or SCNT-hydrops samples
were appropriately methylated when compared with con-
trol AI samples. Generally, there were no differences in
the mean methylation patterns and levels between the
SCNT and SCNT-hydrops groups despite evident pheno-
typic differences. However, close inspection of individual
profiles revealed that within the SCNT-hydrops group,
there were individuals who showed aberrant hypo- or
hypermethylation, particularly in the IGF2 exon 10 DMR,
KCNQ1OT1, SNRPN and HAND1 regions. Aberrant
methylation in any of those genes was not always accom-
panied by aberrant methylation in other regions. Further-
more, two individual that are genetically identical could
be aberrantly methylated in different ways, demonstrating
the stochasticity of the reprogramming defects. At speci-
fic CpG sites, significant differences between SCNT and
AI samples were detected in some genes. It is not possi-
ble to say if these sites represent “hot-spots” for methyla-
tion variation or whether these methylation aberrations
are the cause of some of the abnormal phenotype seen in
SCNT foetuses.
Genes in the BWS locus were of particular interest
because of the variable overgrowth phenotypes seen in
SCNT foetuses and how some of the phenotypes resem-
ble BWS in humans. The methylation profiles of CpG
islands associated with the KCNQ1 and CDKN1C genes
were practically identical between the AI control and
both groups of SCNT, in liver, kidney and adrenal sam-
ples. This suggests that the methylation at these sites is
tightly regulated and they were appropriately methylated
in these SCNT organs, even in those from failing
hydrops pregnancies. Similarly, no differences were
observed for the region associated with ASCL2. This
tight regulation did not extend to the KCNQ1OT1
region located close to the CDKN1C gene in this
imprinted cluster. CpG sites in the KCNQ1OT1 region
showed substantial variation between individuals and a
tendency for SCNT samples to be less methylated at
almost every analyzable CpG site. Taken together, these
results suggest that even within the same locus, some
CpG islands are methylated appropriately in SCNT tis-
sues while others are less so. As it was not possible to
distinguish between the maternal and paternal allele in
c a t t l e ,w ew e r eu n a b l et od e t e r m i n ei ft h ea b e r r a n t
methylation was restricted to one allele or if both were
aberrantly methylated.
Similarly, at the region corresponding to the SNRPN
imprint control region in humans, the methylation levels
were also highly variable between individuals in all
groups. Mean methylation at the majority of CpG sites
in both SCNT groups tended to be lower when com-
pared with the AI group, although not as dramatically
hypomethylated as in early extraembryonic tissues,
(Couldrey and Lee, unpublished data and that of others
[25]). Although there was a tendency for this region to
be incorrectly methylated following SCNT, not all CpG
sites in this region were affected in the same way. An
example of this is the cleavage fragment containing
CpG7-9 which was consistently unmethylated for every
sample in each of the three tissues in all treatment
groups. It is possible that these CpG sites are invariably
protected from epigenetic modification.
Figure 14 DNA methylation across satellite alpha repeat
sequence. Nine cleavage fragments containing 11 out of a total of
16 CpG sites in this region could be analyzed. The cleavage
fragments containing CpG sites 3-4 and 16 could not be
distinguished from each other in the analysis. Therefore, the
proportion of methylation in each of these fragment groups is
represented as an average value.
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tion levels between SCNT and the control group were
detected at specific CpG sites in HAND1, ASCL2 and
the KCNQ1 promoter regions in various tissues. These
differences were very small and the overall methylation
s t a t u so ft h ee n t i r er e g i o ne xamined was not altered so
their biological significance is uncertain. The occurrence
of these very small differences is no higher than would
be expected purely by chance at the 5% level. Only the
HAND1 region showed tissue specific methylation differ-
ences as the adrenal tissues have a noticeably different
pattern compared with the other two tissues. In these
regions, the similarity in methylation pattern between
SCNT and normal tissues suggests that this region has
undergone appropriate reprogramming and that tissue-
specific methylation patterns were successfully established
in this organ. Where there were no tissue-specific methy-
lation differences, the absence of difference in methyla-
tion between AI and SCNT samples is either an
indication of successful reprogramming or that these
regions normally escape global demethylation [23,29,44]
in the pre-implantation embryo and therefore did not
require extensive reprogramming after SCNT.
For imprinted genes, the imprints that mark the paren-
tal origin of each allele are normally established during
gametogenesis, leading to differential methylation of the
male and female gametic DNA in DMRs. The methyla-
tion levels in DMRs have previously been reported to be
~50%. This level of methylation was believed to be due
to the almost complete methylation of one parental allele
versus the non-methylation of the other allele. We found
that for the IGF2 exon 10 DMR, the majority of the CpG
sites were methylated to between 70 to nearly 100% in
the three foetal tissues examined, even in the controls.
Assuming that the paternal allele was completely methy-
lated, this suggests that the maternal allele was progres-
sively methylated during development. One possible
explanation for this is that after additional epigenetic
marks that dictate allele-specific expression are estab-
lished during early embryogenesis, there is no longer the
requirement to maintain the differential marking at the
DMRs so most of the CpG sites in somatic cells then
become progressively methylated. Alternatively, it may be
that only a few CpG sites in the region are required to
be differentially methylated to distinguish the parental
alleles so the non-essential sites become methylated
through methylation spreading.
Comparison of the methylation profiles in non-
imprinted genes and the repetitive DNA satellite regions
showed that in general, these regions appeared to be
appropriately methylated in the SCNT tissue samples
examined. Although satellite sequences are non-coding
a n da r et h o u g h tt ob ek e p th i g h l ym e t h y l a t e di nt h e
genome, not every CpG site was methylated to the same
extent across the region. Despite significant differences
in methylation levels at specific CpG sites between treat-
ment groups, these differences are very small and the
significance in unclear.
An intriguing observation from this study is that in
some genes, there is a surprisingly large variation in the
methylation levels between individuals at practically
every CpG site in the region examined, even between
individuals in the normal control group. This suggests
that there is tolerance for a range of DNA methylation
levels in some genomic regions; whether this translates
to phenotypic variability is unknown. This variability
could be in part, explained by the inherent lower fidelity
(compared with DNA replication) of the DNA mainte-
nance methylation mechanism, which is estimated to be
about 95% for methylation of the newly unmethylated
strand [45]. However, thisd o e sn o te x p l a i nw h yt h e
methylation of certain regions is so tightly regulated.
This variability is not due to heterogeneous tissue sam-
pling as the analyses for multiple genes were carried out
on the same bisulfite-treated DNA sample for each indi-
vidual. In these same samples, other genomic regions
showed very tight invariant methylation at almost all
CpG sites in every individual. In general, consistent with
previous findings [45] CpG islands upstream of tran-
scriptional start sites or near promoters were less
methylated (5-20%) than the two putative DMRs and
satellite sequences, which tended to be methylated to
40-100%.
Previous studies assessing the reprogramming of the
donor nucleus after SCNT have used antibodies raised
against methylcytosine residues to compare global
methylation in the nuclei of SCNT and normal embryos
[27]. This technique only allows visualization of highly
methylated regions which are likely to be repeat
sequences that do not code for functional genes. Subtle
differences in regions present at two copies per genome
will be masked by the overall methylation of highly
repetitive elements. Other techniques which average
DNA methylation levels over the genomic region ana-
lyzed have led to the misconception that DNA methyla-
tion levels are similar at each CpG site across the entire
CpG island. In contrast, the MassARRAY technology is
able, in many instances, to calculate DNA methylation
levels at individual CpG sites reproducibly down to 5%
for each informative CpG unit [38]. However, because
the MassARRAY method depends on sequence-specific
cleavage of derived RNA products, this technology is
unable to analyze the methylation at every CpG site
when suitable cleavage sites are unavailable such as in
high density CpG regions. Bisulfite sequencing will be a
useful adjunct when these regions warrant further exam-
ination. The success of both techniques however, is
dependent on being able to design primers that flank
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selves must bind to regions which do not contain CpG
sites. For some CpG islands that are large (up to ~8 kb),
this is not always possible and other methods must be
devised to study such regions.
The ability to analyze large numbers of samples and
genes and quantify the level of methylation at specific
CpG sites allows a more accurate assessment of methy-
lation profiles in the populations of interest. The tech-
nology has enabled us to appreciate detail previously
unrealized: a) some CpG sites are always protected from
methylation whilst others tend to be highly methylated;
b) methylation at some CpG site(s) within a region
show high variability between individuals whilst others
are invariably methylated in every individual; c) some
regions, such as the KCNQ1OT1 site in adrenal tissues
and DIO3 in all tissues show apparent periodicity in the
methylation profile, with highly-methylated sites inter-
spersed with lowly-methylated sites; d) tissue-specific
methylation patterns were uncommon. It remains for
the biological significance of these observations to be
determined.
The detail revealed by this method of DNA methyla-
tion analysis calls into question whether the practice of
reporting the average methylation level across all CpG
sites within a region and comparing this value between
experimental samples is meaningful. This could poten-
tially mask methylation differences between experimen-
tal groups at CpG sites that may be important for
regulating chromatin structure and hence, gene expres-
sion. CpG sites that are invariably protected from
methylation, or those which are always methylated are
not evident when averaging methylation levels across a
region. Subtle tissue-specific differences may also be
masked. Furthermore, the biological significance of aver-
aged methylation levels in a region is unclear.
Conclusions
We have used the MassARRAY technology to look at
multiple regions in the genome and found that for
SCNT foetuses that survived to mid-gestation, albeit
with phenotypic abnormalities in some cases, the methy-
lation patterns were very similar to those of naturally
conceived foetuses, at least for the three organs exam-
ined. This suggests that in those foetuses, the majority
of these sites in the genome have been appropriately
“reprogrammed”.H o w e v e r ,t h e r ew e r et w or e g i o n s
located in imprinted gene clusters (BWS and PWS loci)
where SCNT samples tended to be hypomethylated.
This implies the importance of these two region in regu-
lating normal foetal development and growth. Similar
observations of aberrant methylation in the BWS locus
in children arising from human IVF is further evidence
of the susceptibility of this region to external influence.
We cannot yet with confidence predict the developmen-
tal outcome of a SCNT foetus from its epigenetic state
at any stage; it is just a snap-shot of the dynamic nature
of the epigenetic status of the genome. We are far from
understanding how DNA methylation patterns relate to
phenotypic outcomes in entire organisms.
Methods
Production and collection of foetal tissues
All manipulations of animals involved in the present
study were conducted in accordance with the regula-
tions of the New Zealand Animal Welfare Act of 1999.
SCNT embryos were produced essentially as previously
described [40]. An adult skin fibroblast cell line
(AESF-1) from a high genetic merit Friesian bull was
used as nuclear donor. After in vitro culture for 7 days,
the embryos were transferred to synchronized recipients
and pregnancy establishment determined at Day 35 of
gestation by trans-rectal ultrasound scanning. Pregnan-
cies were monitored monthly by ultrasound scanning
until Day 120. From then, the animals were monitored
closely by rectal palpation for the development of
hydrallantois. SCNT pregnancies that were diagnosed
with hydrops were terminated by slaughter at the abat-
toir. Viable SCNT pregnancies from the same cohort
but without hydrops were also terminated at around the
same gestation as those with hydrops. Additional sam-
ples from SCNT-hydrops pregnancies at similar stages
of gestation generated from several other donor cell
lines were included in the study. Thus, the group
SCNT-hydrops consisted of SCNT foetuses derived
f r o mt h eA E S F - 1l i n ea sw e l la sf r o mf i v eo t h e rc e l l
lines of both sexes and of different breeds. This allowed
us to investigate whether the DNA methylation status is
similar or different in SCNT-hydrops foetuses with dif-
ferent genetic backgrounds. Control pregnancies were
generated by artificial insemination (AI) with frozen
semen from the bull which provided the AESF-1 donor
cells and foetal tissues were collected at the equivalent
stage of gestation as the SCNT foetuses. The uteri and
its contents were recovered after slaughter of the recipi-
ent dams. Gross foetal and placental morphology was
recorded and foetal and placental tissue samples col-
lected and snap-frozen in liquid nitrogen. For this study,
three organs, the kidney, liver and adrenal glands, which
commonly show growth disregulation in SCNT foetuses,
were used (AI, n = 5; SCNT, n = 6 and SCNT-hydrops,
n = 4 from the AESF-1 line and n = 6 from other cell
lines).
Identification of CpG islands for analysis
Promoter regions (up to 10 kb upstream of the putative
transcription start site) and transcribed regions of
selected genes were analysed for the presence of CpG
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> 0.60, C+G content > 50%, length > 200 bp) using
Emboss on EBI website.
Primers were designed (table 1), using MethPrimer, to
flank and amplify CpG island sequences in genes of
interest, as described [46]. Primer sequences contained
at least four Cs that were not in CpG pairs and no CpG
sites. The regions of interest chosen include: a) a region
spanning the putative transcription start site of ASCL2,
a gene associated with placental development; b) a
region in exon 10 of IGF2 (GenBank accession no.
X53553) that is differentially methylated [47]; c) a region
spanning the putative transcription start site of KCNQ1;
d )5 0 0b po ft h eC p Gi s l a n dc o r r e s p o n d i n gt ot h e
human KCNQ1OT1 DMR; e) 1-0.5 kb upstream of
exon 1 of HAND1, coding for a transcription factor
associated with trophoblast differentiation, cardiogenesis
and the development of neural crest derivatives; f) part
of exons 3 and 4 and intron 3 of CDKN1C; g) a region
beginning upstream of exon 1, covering exon 1 and part
of intron 1 of SNRPN (GenBank accession no.
AY743660); h) a region at the transcriptional start site
for the DIO3 antisense transcript, covering the polyA
signal of DIO3 gene, which codes for iodothyronine
Table 1 PCR primers used for Sequenom analysis
Name Sequence Chromosomal location Product size (bp)
SNRPN_L AGGAAGAGAGTTGGGAGGTATTATTTTGGGTTGAA ChrU:24360-23919 437
SNRPN_R CAGTAATACGACTCACTATAGGGAGAAGGCTAACCCCAAACCTCCAAAAATTATC
IGF2_L AGGAAGAGAGGGGTATTTGGGGTAGTTTAGG Chr29:3633319-3633749 521
IGF2_R CAGTAATACGACTCACTATAGGGAGAAGGCTATTCTAATCCCCTCAACCAAATAAA
CDKN1C_L AGGAAGAGAGGTAGTGGTATATTTAGTTGGAAGTTGTAGT Chr29:2954381-2953897 485
CDKN1C_R CAGTAATACGACTCACTATAGGGAGAAGGCTTAGTTAGGTTAGAGTTAGTT
HAND1_L AGGAAGAGAGGAGAAAGGTTTTTGGGGATAAAATT Chr7:1101938-1101390 549
HAND1_R CAGTAATACGACTCACTATAGGGAGAAGGCTCAAACCCTACAACTAACAAAACATCC
ASCL2_L AGGAAGAGAGGTATTAGGGGGAGTTTTGGTAG Chr29:3526331-3526685 354
ASCL2_R CAGTAATACGACTCACTATAGGGAGAAGGCTCTAAAACCCCAAATTCACCAACTTC
KCNQ1_L AGGAAGAGAGGGGTTTGGTTAAGAAGTGTTTTTTTT Chr29:3365714-3365215 500
KCNQ1_R CAGTAATACGACTCACTATAGGGAGAAGGCTAATCAAACCCACAAAACCCTAAACTT
Dio3_L AGGAAGAGAGTTTGTATTTGTTTGGTTTGTTTTAA Chr21:1453786-1454238 453
Dio3_R CAGTAATACGACTCACTATAGGGAGAAGGCTCAACTCTTCATCAACAATAAAACTC
KCNQ1OT1_L AGGAAGAGAGTAGTTGATTGGATAGTTTGTAGGGG Chr29:3133697-3133352 346
KCNQ1OT1_R CAGTAATACGACTCACTATAGGGAGAAGGCTCCACAAATATTCCTCAAAATCACTC
STAT5_L AGGAAGAGAGTTTGTTAGAGGTAGTTGATTTTTGAGGA Chr19:872990-873467 478
STAT5_R CAGTAATACGACTCACTATAGGGAGAAGGCTAAAAAAACAAAACACTCCCTCTCTC
GR_R CAGTAATACGACTCACTATAGGGAGAAGGCTAATTTTCTCTATAATTTCTCTTCTTACC Chr7: 2747426-2747103 324
GR_L AGGAAGAGAGTTTTTTTGAAGTTTTTTTAGAGGG
DKK_001_L AGGAAGAGAGTTTTTTTTGAGTTTTTTTGAGATGA Chr26:336954-336488 467
DKK_001_R CAGTAATACGACTCACTATAGGGAGAAGGCTCACTTAAACACCCAATACCACACT
DKK_002_L AGGAAGAGAGGTGTGGTATTGGGTGTTTAAGTGT Chr26: 336510-336157 534
DKK_002_R CAGTAATACGACTCACTATAGGGAGAAGGCTCCTAAAATCCTTTCTAAAAATCCTC
CSF-1_L AGGAAGAGAGGTAGTTTTTGGAGTAGTTGTAGGGT Chr3: 629601-630161 561
CSF-1_R CAGTAATACGACTCACTATAGGGAGAAGGCTCAAAATAATTTCCCATAAACCACATAC
Satellite I_L AGGAAGAGAGTGTAGATTGGGGATAGGAGAGTTAG N/A 345
Satellite I_R CAGTAATACGACTCACTATAGGGAGAAGGCTCCTACTTTATCTAAAAAAAATTACCTTCC
Satellite II_L AGGAAGAGAGTTTGGTTTTAGGTTGGGAGTTTAAAG N/A 278
Satellite II_R CAGTAATACGACTCACTATAGGGAGAAGGCTAAAACAACAATCAAACACCACTCAC
Satellite alpha_L AGGAAGAGAGTTTTTTTTGATTTGGATAGGAGGG N/A 279
Satellite alpha_R CAGTAATACGACTCACTATAGGGAGAAGGCTACTATATTTAAAACCAAAAATTTTTCC
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overlapping amplicons) at the transcriptional start site
of DKK-1, a potent inhibitor of the WNT signalling
pathway which is highly expressed in mesenchymal
lineages and may mediate the inductive interactions
between the mesenchyme and the epithelium; j) a region
10 kb upstream of the transcriptional start site of
STAT5a, a signaling protein for many cytokines and
growth factors; k) a region in the bovine GR gene
equivalent to the rat exon 17 promoter region, pre-
viously shown to be epigenetically modified in rat pups
by maternal behaviour towards them [48-50]; l) a region
near the transcriptional start site of CSF-1, a cytokine
implicated in the development of certain haematopoietic
cell lineages; m) a region spanning a CpG island in
satellite sequence I (GenBank accession no. J00032); n)
a region spanning a CpG island in satellite sequence II
(GenBank accession no. X03116); and o) a region span-
ning a CpG island in satellite sequence alpha (GenBank
accession no. AJ293510). The regions chosen for
KCNQ1OT1, GR, IGF2 exon 10 DMR, and SNRPN
were those where DNA methylation had previously been
analyzed in the human, mouse, rat or cow. For ASCL2,
KCNQ1, DIO3, DKK1 and CSF1, where there have been
no previous data, we chose to analyze DNA methylation
in CpG islands near the transcription start sites. Due to
the high C+G content and density of CpG sites in the
C D K N 1 Cg e n e ,i tw a sn o tp o s s i b l et od e s i g np r i m e r s
t h a tc o u l db eu s e dw i t hb i s u l f i t e - c o n v e r t e dD N At h a t
would span < 500 bp in the promoter region. The intra-
genic region analyzed in CDKN1C was as close to the
promoter as possible.
DNA extraction
Tissues were ground up in liquid nitrogen to a powder
to ensure homogeneity for DNA sampling. Between 20
and 100 mg of tissue was then used for DNA extraction
using either phenol/chloroform [51] or a DNeasy kit fol-
lowing the manufacturer’s protocol (Qiagen, Austin,
TX). DNA concentration and purity was measured
using the Nanodrop spectrophotometer (Thermo Scien-
tific, DE, USA)
Analysis of DNA methylation
DNA samples were analyzed using the methods
described [38,52,53]. Briefly, 1 μg DNA was bisulfite trea-
ted using the EZ-96 DNA Methylation gold kit (Zymo,
CA, USA) to produce methylation-dependent sequence
variations of C to T and regions of interest were ampli-
fied using T7 tagged PCR primers. PCR conditions were:
200 nM of forward and reverse primers, 200 μM of each
d N T P ,1 ×Q i a g e nH o t S t a rb u f f e r ,0 . 2UQ i a g e nH o t S t a r
Taq polymerase and 2 μl bisulfite converted DNA per
reaction in a total volume of 10 μl. PCR cycling
conditions were: 94°C 15 min followed by 45 cycles of
94°C, 20 sec; 56°C, 30 sec; 72°C, 1 min with a final exten-
sion at 72°C for 3 min. PCR products were analyzed by
agarose gel electrophoresis to confirm successful amplifi-
cation. In vitro amplification and transcription was per-
formed on the reverse strand using 2 μlo fP C Rp r o d u c t
using T7 DNA and RNA polymerases and a simultaneous
U specific cleavage by RNAse A. Approximately 20 nl of
each sample was spotted onto Sequenom MassARRAY
chips and subject to mass spectrometry. The efficiency
of bisulfite conversion was determined by assessing
the quality of the raw data. Incomplete bisulfite conver-
sion generates mass peaks at a mass/charge ratio of
16, 32, 48, etc. greater than the expected peaks, in addi-
tion to the expected peaks. Such data were infrequent
and excluded from the analyses.
Statistical analysis
Spectra were analyzed using proprietary peak picking
and signal-to-noise ratio calculations. The relative
methylation of the CpG sites was then calculated (Epi-
TYPER, Sequenom, CA, USA) by dividing the peak
intensity (area under the peak) of the fragment repre-
senting the original methylated DNA, by the sum of the
intensities of the peaks representing both methylated
and non-methylated DNA. Mean DNA methylation
levels for each fragment were compared using the least
significant differences calculated from the analysis of
variance across the three treatment groups in each tis-
sue examined. The mean methylation level across the
region contained in the amplicon was also calculated for
each gene and compared pair-wise between treatment
groups for each tissue using the t-test. Results are pre-
sented as mean +/- standard error of the mean (S.E.M).
Note
DNA methylation levels at CpG sites in the
amplicons
Each CpG site or groups of sites which could be ana-
lyzed by Sequenom MassARRAY are arranged in the
order that they appear in the DNA sequence, 5’ to 3’ on
the x-axis. Where there are more than one CpG sites in
a fragment, the numbered CpG sites are grouped
together in one position on the x-axis and the propor-
tion of methylation refers to the most methylated site
(Sequenom EpiTYPER 1 software). The y-axis represents
the proportion of methylation at specific CpG sites in
the region analyzed. The error bars represent the SEM
and arrows indicate CpG sites where there is significant
difference (P < 0.05) among the treatment groups. a)
adrenal, b) kidney and c) liver tissues, d) average methy-
lation in the genomic region represented by the ampli-
con; columns with different labels are significantly
different from each other (P < 0.05). AI: AI controls;
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Page 15 of 17SCNT: SCNT samples from apparently viable foetuses;
SCNT-hydrops: SCNT samples from foetuses termi-
nated because of hydrops.
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